ENCORAFENIB
Total Payments
$18,699
Transactions
3
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $9,500 | 1 | 0 |
| 2017 | $9,199 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $18,699 | 3 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE IB AND OR II MULTI CENTER OPEN LABEL DOSE ESCALATION STUDY OF LGX818 AND CETUXIMAB OR LGX818 BYL719 AND CETUXIMAB IN PATIENTS WITH BRAF MUTANT METASTATIC COLORECTAL CANCER | Novartis Pharmaceuticals Corporation | $9,500 | 0 |
| A PHASE I MULTICENTER OPEN LABEL DOSE ESCALATION STUDY OF ORAL LGX818 IN ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BRAF MUTANT MELANOMA | Novartis Pharmaceuticals Corporation | $7,460 | 0 |
| A PHASE II MULTI CENTER OPEN LABEL STUDY OF SEQUENTIAL SINGLE AGENT LGX818 FOLLOWED BY A RATIONAL COMBINATION WITH TARGETED AGENTS AFTER PROGRESSION TO OVERCOME RESISTANCE IN ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BRAF V600 MELANOMA | Novartis Pharmaceuticals Corporation | $1,739 | 0 |
Top Doctors Receiving Payments for ENCORAFENIB
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Salt Lake City, UT | $18,699 | 3 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $18,699
- Total Doctors 0
- Transactions 3
About ENCORAFENIB
ENCORAFENIB is a drug associated with $18,699 in payments to 0 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2018. In 2018, $9,500 was paid across 1 transactions to 0 doctors.
The most common payment nature for ENCORAFENIB is "Unspecified" ($18,699, 100.0% of total).
ENCORAFENIB is associated with 3 research studies, including "A PHASE IB AND OR II MULTI CENTER OPEN LABEL DOSE ESCALATION STUDY OF LGX818 AND CETUXIMAB OR LGX818 BYL719 AND CETUXIMAB IN PATIENTS WITH BRAF MUTANT METASTATIC COLORECTAL CANCER" ($9,500).